Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
Clinical Trials Arena on MSN2d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpointBioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...
SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...
PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...
San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...
Zacks.com on MSN1d
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric StudyBased on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a ...
We all experience cravings. Sometimes, our cravings prompt undesirable behaviors, which can contribute to negative ...
Kymyz is naturally rich in beneficial bacteria and yeast that support gut health. Its mild alcohol content — a byproduct of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback